Not finding it? Sign in to also search OpenAlex live.
-
HOPE treatment prior to organ transplant alters key immune modulators in patients receiving liver transplantation2025 Zeitschrift für Gastroenterologie conference-paper Medicine Organ Transplantation Techniques and Outcomes
Johanna Reißing, Maike R. Pollmanns, Johan Hohenschwert, Dominik Krautgartner, Felix Oldhafer, Ulf P. Neumann, +4 more
0citations -
Regulatory T Cell Depletion Using a CRISPR Fc-Optimized CD25 Antibody2022 International Journal of Molecular Sciences article Immunology and Microbiology T-cell and B-cell Immunology Open access
Marit J van Elsas, Johan M. S. van der Schoot, Alexander Bartels, Kas Steuten, Duco van Dalen, Zacharias Wijfjes, +5 more
5citations -
Characterization and comparison of innate and adaptive immune responses at vaccine sites in melanoma vaccine clinical trials2021 Cancer Immunology Immunotherapy article Immunology and Microbiology Immunotherapy and Immune Responses Open access
Marit Martina Melssen, Karlyn E. Pollack, Max O. Meneveau, Mark E. Smolkin, Joel Pinczewski, Alexander F. Koeppel, +6 more
19citations -
52MO A randomized phase II trial of durvalumab and tremelIMUmab with gemcitabine or gemcitabine and cisplatin compared to gemcitabine and cisplatin in treatment-naïve patients with CHolangio- and gallbladdEr Carcinoma (IMMUCHEC)2022 Annals of Oncology article Medicine Cholangiocarcinoma and Gallbladder Cancer Studies Open access
A. Vogel, S. Boeck, O. Waidmann, Michael Bitzer, P. Wenzel, S. Belle, +13 more
9citations -
Histology independent drug development – Is this the future for cancer drugs?2023 Cancer Treatment Reviews article Mathematics Statistical Methods in Clinical Trials Open access
Lucinda Jane Billingham, Theodor Framke, Alastair Greystoke, Eivind J. Hovig, Philippe Page, Elias Péan, +4 more
6citations -
6P Response and survival according to the interferon-gamma (IFN-γ) signature and tumor mutational burden (tmb) in the PRADO trial testing neoadjuvant ipilimumab and nivolumab in stage III melanoma
Reijers, P. Dimitriadis, J.J. Traets, Robyn P.M. Saw, J.M. Versluis, Thomas E. Pennington, +14 more
4citations -
LBA32 Principal results of the EORTC-1508 trial: A phase II randomised, multicentre study of bevacizumab vs atezolizumab and bevacizumab with acetylsalicylic acid or placebo in recurrent platinum-resistant ovarian, fallopian tube or primary peritoneal adenocarcinoma
Susana N. Banerjee, P.B. Ottevanger, Apostolos Sarivalasis, Romuald Le Scodan, Ana Montes, Judith R. Kroep, +9 more
4citations -
Tumor immune microenvironmental characteristics in Human Epidermal Growth Factor-2 (HER2) positive esophageal adenocarcinoma: A comparative analysis and biomarker study
Charlotte I. Stroes, Sybren L. Meijer, Geert‐Jan Creemers, Gerrit K. J. Hooijer, Nadia Haj Mohammad, Maartje Los, +6 more
3citations -
1095P Associations between baseline biomarkers and 3-year survival in the PRADO trial testing neoadjuvant ipilimumab and nivolumab in stage III melanoma
Irene L. M. Reijers, Petros Dimitriadis, Alexander Maxwell Menzies, Ellen Kapiteijn, Astrid A.M. van der Veldt, Karijn P.M. Suijkerbuijk, +13 more
2citations -
NCAPH as an onco-structural hub linking chromatin architecture to metabolic reprogramming, immune evasion, and therapy resistance2026 Critical Reviews in Oncology/Hematology review Biochemistry, Genetics and Molecular Biology Chromatin Remodeling and Cancer
Zhaopeng Song, Yitong Xia, Guifeng Zhang, Zheng Wang, Jingkun Yang, Wenyong Fan
2citations